Robin Graf

Robin Graf

Auto-generated profile, based on publicly available information

Robin Graf

Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 January 2016 in BMC Biotechnology
Verified
Journal Article
Open access
PDF file
VCVan Trung Chu
Van Trung Chu
TWTimm Weber
Timm Weber
RGRobin Graf
Robin Graf
TSThomas Sommermann
Thomas Sommermann
KPKerstin Petsch
Kerstin Petsch
RKRalf Kuehn
Ralf Kuehn
The CRISPR/Cas9 system is increasingly used for gene inactivation in mouse zygotes, but homology-directed mutagenesis and use of inbred embryos are less established. In particular, Rosa26 knock-in alleles for the insertion of transgenes in a genomic ‘safe harbor’ site, have not been produced. Here we applied CRISPR/Cas9 for the knock-in of 8–11 kb inserts into Rosa26 of C57BL/6 zygotes. We found that 10–20 % of live pups derived from microinjected zygotes were founder mutants, without apparent off-target effects, and up to 50 % knock-in embryos were recovered upon coinjection of Cas9 mRNA and protein. Using this approach, we established a new mouse line for the Cre/loxP-dependent expression of Cas9. Altogether, our protocols and resources support the fast and direct generation of new Rosa26 knock-in alleles and of Cas9-mediated in vivo gene editing in the widely used C57BL/6 inbred strain.

11 October 2016 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
VCVan Trung Chu
Van Trung Chu
RGRobin Graf
Robin Graf
TWTristan Wirtz
Tristan Wirtz
TWTimm Weber
Timm Weber
JFJeremy Favret
Jeremy Favret
KRKlaus Rajewsky
Klaus Rajewsky
Significance: Efficient clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR associated protein 9 (Cas9)-mediated mutagenesis is necessary for robust genetic screening in primary cells and requires sufficiently high levels of Cas9 and reliable single guide RNAs (sgRNAs). We provide a sgRNA design tool that selects high-fidelity sgRNAs and a Cas9 transgenic mouse line that expresses Cas9 at high levels in all cells analyzed. Using this system, we achieved an average knockout efficiency of 80% in primary B cells and established a robust CRISPR/Cas9-mediated genetic screening system that can be adapted to other primary cell types.

1 January 2019 in Cell Reports
Verified
Journal Article
Open access
RGRobin Graf
Robin Graf
XLXun Li
Xun Li
VCVan Trung Chu
Van Trung Chu
KRKlaus Rajewsky
Klaus Rajewsky
Cas9 nucleases can be programmed with single guide RNAs (sgRNAs) to mediate gene editing. High CRISPR/Cas9-mediated gene knockout efficiencies are essential for genetic screens and critically depend on the properties of the sgRNAs used. The specificity of an sgRNA is defined by its targeting sequence. Here, we discovered that two short sequence motifs at the 3' end of the targeting sequence are almost exclusively present in inefficient sgRNAs of published sgRNA-activity datasets. By specific knock-in of sgRNA target sequences with or without these motifs and quantitative measurement of knockout efficiency, we show that the presence of these motifs in sgRNAs per se results in a 10-fold reduction of gene knockout frequencies. Mechanistically, the cause of the low efficiency differs between the two motifs. These sequence motifs are relevant for future sgRNA design approaches and studies of Cas9-DNA interactions.

15 February 2019 in Science
Verified
Journal Article
Closed access
PDF file
RGRobin Graf
Robin Graf
JSJane Seagal
Jane Seagal
KOKevin L. Otipoby
Kevin L. Otipoby
KLKong-Peng Lam
Kong-Peng Lam
SASalah Ayoub
Salah Ayoub
KRKlaus Rajewsky
Klaus Rajewsky
B1 or B2? The BCR decides: Immunological B cells are generally divided into two major subsets. B2 cells generate specific antibodies against foreign antigens in secondary lymphoid organs. B1 cells, found predominantly in the peritoneal and pleural cavities, instead produce “natural” antibodies as part of the innate immune system. Two models to explain this split exist: the “lineage model,” wherein both subsets have distinct progenitors, and the “selection model,” in which fates are directed by different B cell antigen receptors (BCRs). Graf et al. provide support for the selection model using a transgenic system in which BCR specificities can be changed. Mature B2 cells differentiated into functional B1 cells when a self-reactive B1 BCR was swapped in, in the absence of B1 lineage precommitment. Science , this issue p. 748

3 June 2022 in Science Advances
Verified
Journal Article
Open access
NTNgoc Tung Tran
Ngoc Tung Tran
EDEric Danner
Eric Danner
XLXun Li
Xun Li
RGRobin Graf
Robin Graf
MLMikhail Lebedin
Mikhail Lebedin
VCVan Trung Chu
Van Trung Chu
While CRISPR-Cas9 is key for the development of gene therapy, its potential off-target mutations are still a major concern. Here, we establish a “spacer-nick” gene correction approach that combines the Cas9 D10A nickase with a pair of PAM-out sgRNAs at a distance of 200 to 350 bp. In combination with adeno-associated virus (AAV) serotype 6 template delivery, our approach led to efficient HDR in human hematopoietic stem and progenitor cells (HSPCs including long-term HSCs) and T cells, with minimal NHEJ-mediated on-target mutations. Using spacer-nick, we developed an approach to repair disease-causing mutations occurring in the HBB , ELANE , IL7R , and PRF1 genes. We achieved gene correction efficiencies of 20 to 50% with minimal NHEJ-mediated on-target mutations. On the basis of in-depth off-target assessment, frequent unintended genetic alterations induced by classical CRISPR-Cas9 were significantly reduced or absent in the HSPCs treated with spacer-nick. Thus, the spacer-nick gene correction approach provides improved safety and suitability for gene therapy.

2 January 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
HEHelena Escobar
Helena Escobar
SFSilvia Di Francescantonio
Silvia Di Francescantonio
JSJulia Smirnova
Julia Smirnova
RGRobin Graf
Robin Graf
SMStefanie Müthel
Stefanie Müthel
SSSimone Spuler
Simone Spuler
Dystrophy-associated fer-1-like protein (dysferlin) conducts plasma membrane repair. Mutations in the DYSF gene cause a panoply of genetic muscular dystrophies. We targeted a frequent loss-of-function, DYSF exon 44, founder frameshift mutation with mRNA-mediated delivery of SpCas9 in combination with a mutation-specific sgRNA to primary muscle stem cells from two homozygous patients. We observed a consistent >60% exon 44 re-framing, rescuing a full-length and functional dysferlin protein. A new mouse model harboring a humanized Dysf exon 44 with the founder mutation, hEx44mut, recapitulates the patients’ phenotype and an identical re-framing outcome in primary muscle stem cells. Finally, gene-edited murine primary muscle stem-cells are able to regenerate muscle and rescue dysferlin when transplanted back into hEx44mut hosts. These findings are the first to show that a CRISPR-mediated therapy can ameliorate dysferlin deficiency. We suggest that gene-edited primary muscle stem cells could exhibit utility, not only in treating dysferlin deficiency syndromes, but also perhaps other forms of muscular dystrophy.